Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Gains from Sales and Divestitures: 2019-2023

Historic Gains from Sales and Divestitures for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to $3.4 million.

  • ADC Therapeutics' Gains from Sales and Divestitures fell 12.72% to $3.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $3.4 million, marking a year-over-year decrease of 12.72%. This contributed to the annual value of $553 for FY2022, which is 4.14% up from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Gains from Sales and Divestitures is $3.4 million, which was up 9.41% from $3.1 million recorded in Q2 2023.
  • ADC Therapeutics' 5-year Gains from Sales and Divestitures high stood at $3.9 million for Q3 2022, and its period low was $329 during Q4 2019.
  • Over the past 3 years, ADC Therapeutics' median Gains from Sales and Divestitures value was $2.2 million (recorded in 2021), while the average stood at $2.3 million.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first skyrocketed by 75.71% in 2022, then decreased by 12.72% in 2023.
  • ADC Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $329 in 2019, then reached $531 in 2021, then increased by 4.14% to $553 in 2022, then declined by 12.72% to $3.4 million in 2023.
  • Its last three reported values are $3.4 million in Q3 2023, $3.1 million for Q2 2023, and $2.8 million during Q1 2023.